ClinicalTrials.gov
ClinicalTrials.gov Menu

In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02582385
Recruitment Status : Completed
First Posted : October 21, 2015
Last Update Posted : October 21, 2015
Sponsor:
Information provided by (Responsible Party):
Carine DE PREZ, Brugmann University Hospital

Brief Summary:
The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Condition or disease Intervention/treatment
Amyotrophic Lateral Sclerosis Other: in-situ cytokine expression

Study Type : Observational
Actual Enrollment : 5 participants
Time Perspective: Retrospective
Official Title: In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis
Study Start Date : October 2012
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015


Group/Cohort Intervention/treatment
Amyotrophic lateral sclerosis (ALS)
Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
Other: in-situ cytokine expression
Control
Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
Other: in-situ cytokine expression



Primary Outcome Measures :
  1. in situ cytokine detection: interleukin 18 [ Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 ]
    IHC detection on histopathology sections of paraffin embedded brain tissue.

  2. in situ cytokine detection: interleukin 1 [ Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 ]
    IHC detection on histopathology sections of paraffin embedded brain tissue.

  3. in situ cytokine detection: interleukin 6 [ Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 ]
    IHC detection on histopathology sections of paraffin embedded brain tissue.

  4. in situ cytokine detection:TNF-a [ Time Frame: retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 ]
    IHC detection on histopathology sections of paraffin embedded brain tissue.


Biospecimen Retention:   Samples Without DNA
Archived/residual histopathology sections and paraffin blocks entirely from residual autopsy material. Archived material involves old cases (autopsied between 2000 and 2005). All autopsies were conducted within the legal frame of the then applicable laws. There is no reference whatsoever to names or identifications of the deceased patients (anonymous samples).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Archived/residual histopathology slides and paraffin blocks from residual autopsy material from patients who died with amyotrophic lateral sclerosis.
Criteria

Inclusion Criteria:

  • patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02582385


Locations
Belgium
CHU Brugmann
Brussels, Belgium, 1020
Sponsors and Collaborators
Brugmann University Hospital
Investigators
Principal Investigator: Hazim Kadhim, MD, PhD CHU Brugmann

Responsible Party: Carine DE PREZ, Head of clinic, Brugmann University Hospital
ClinicalTrials.gov Identifier: NCT02582385     History of Changes
Other Study ID Numbers: CHUB-ALS
First Posted: October 21, 2015    Key Record Dates
Last Update Posted: October 21, 2015
Last Verified: October 2015

Keywords provided by Carine DE PREZ, Brugmann University Hospital:
Amyotrophic lateral sclerosis (ALS)
Cytokines
Neuropathology

Additional relevant MeSH terms:
Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases